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Background: Guava pomace is an example of the processing waste generated after the manufacturing process
from the juice industry that could be a source of bioactives. Thus, the present investigation was carried out in order
to evaluate the anti-inflammatory and antinociceptive potential and determinate the main phenolic compounds of
a guava pomace extract (GPE).
Methods: The anti-inflammatory activity was evaluated by carrageenan, dextran, serotonin, histamine-induced paw
edema and neutrophils migration in the peritoneal cavity models. Acetic acid-induced abdominal writhing and
formalin test were performed to investigate the antinociceptive effects. In addition, the content of total phenolic
and of individual phenolic compounds was determined by GC/MS.
Results: GPE showed anti-inflammatory activity by carrageenan, dextran, serotonin, histamine-induced paw edema
and neutrophils migration in the peritoneal cavity models (p < 0.05). GPE also demonstrated antinociceptive activity
by acetic acid-induced abdominal writhing and formalin test (p < 0.05). The total phenolic value was 3.40 ± 0.09 mg
GAE/g and epicatechin, quercetin, myricetin, isovanilic and gallic acids were identified by GC/MS analysis.
Conclusions: The presence of bioactive phenolic compounds as well as important effects demonstrated in animal
models suggest that guava pomace could be an interesting source of anti-inflammatory and analgesic substances.
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Psidium guajava, usually known as guava, is an import-
ant tropical fruit mostly consumed fresh. The Guava in-
dustry provides a variety of processed products, such as
beverages, syrup, ice-cream, jams, jellies, toffee, juice,
and dehydrated and canned products. Since the world-
wide production of guava is estimated at about 500,000
metric tons, considerable amounts of waste from this in-
dustry are also generated and simply discarded to the
environment [1].
A great variety of agro-industrial residues from many
species of fruits are wasted every year, polluting the en-
vironment [2,3]. Efforts have been made to use residues
to generate several value-added products, such as bio-
active substances, used by food, cosmetic and pharma-
ceutical industries [3,4]. Guava pomace is an example of* Correspondence: dennycarina@hotmail.com
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reproduction in any medium, provided the orthe processing waste generated after the manufacturing
process and represents up to 15% of the original fruit [1].
In addition to being an import food crop, guava is an
important medicinal plant that has been traditionally used
for a long time in countries of the tropical America [1,5].
This species is commonly used to treat gastrointestinal
and respiratory disturbances and as an anti-inflammatory.
Several different studies have been developed to sup-
port its popular use [5,6]. Revolving around its anti-
inflammatory and analgesic properties, most studies refer
to the leaf extracts, which have been evaluated on several
experimental models [5,7-9]. A preliminary study about
the anti-inflammatory and antinociceptive activity of
guava fruits was reported by Sen et al. [7]. Despite this,
the precise effects of P. guajava and the signaling path-
ways involved remain unknown. In general, biological
properties of guava have been already associated with its
phenolic compounds, such as protocatechuic, ferulic, as-
corbic, gallic and caffeic acids and quercetin [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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industrial residue consists of a mixture of peel, seed and
pulp that is rich in phenolic compounds with antioxi-
dant capacity [2]. Therefore, due to the great potential
demonstrated in the literature through studies that identi-
fied important bioactive compounds, either in the fruit,
leaves or the pomace, the purpose of the present study was
to determine the anti-inflammatory and antinociceptive
potential by different in vivo models, as well as the total
phenolic content, and the main constituents by GC/MS of
the guava pomace extract.
Methods
Plant material
The pomace from the processing of guava (Psidium
guajava L. - Myrtaceae) was provided by “Cepêra - Agro
Industrial Ibitirama Ltda”, a food company located in
the City of Monte Alto, SP, Brazil, in March 2009. The
material (1745.08 g) was lyophilized, homogenized,
weighed and stored at −18°C.
Preparation of the extract
The air-dried and powdered guava pomace (100 g) was
extracted with 160 mL of ethanol (EtOH) and 40 mL of
water (H2O) by using an ultrasound for 30 minutes (3
times). The obtained guava pomace extract (GPE) was
filtered and evaporated using a rotary evaporator and
freeze dryer to provide the crude dried extract. The
dried extract was stored at −18°C until its use.
Determination of the total phenolic content
The total phenolic content was determined by the Folin-
Ciocalteu method [10]. The analysis was performed
following the spectrophotometric method, using Folin-
Ciocalteau’s reagent (Dinâmica Química Contemporânea,
Diadema, SP, Brasil) and gallic acid (Sigma-Aldrich, St.
Louis, MO, USA) as standard.
A volume of 0.5 mL of the extract and 2.5 mL of Folin-
Ciocalteu’s reagent (diluted in water 1:10) was placed in
tubes and, after five minutes, 2 mL of sodium carbonate
(4%) were added. The tubes were kept away from the light
and, after two hours, the absorbance was read in a spec-
trophotometer (Shimadzu, Kyoto, Japan) at 740 nm. The
total phenolic content was expressed as mg of gallic acid
equivalent (GAE) per g of extract (mg GAE/g).
Gas chromatography with mass spectrometry (GC-MS)
GPE was purified with solid phase extraction (SPE DSC-
18 Discovery, 2 g, Supleco, Sigma-Aldrich, St. Louis,
MO, EUA) and 100 μL of N-methyl-N-(trimethylsilyl)
trifluoroacetamide (MSTFA) were added for derivatiza-
tion. The silanized sample was analyzed in a gas chro-
matograph (Shimadzu GC 2010) coupled with a mass
spectrometer (Shimadzu QP 2010 Plus) and equippedwith a capillary column (30 m × RTX 5MS 0.25 mm ×
0.25 μm). The programming temperature started at 80°C
(1 min) at a heating rate of 20°C min-1 and reached
250°C (1 min), going to to 300°C (5 min) at a rate of
6°C min-1, 310°C (5 min) at a rate of 15°C min-1 and
320°C (10 min) at a rate of 20°C min-1, at a total of
40 minutes of analysis. Helium was used as the carrier
gas. The injector temperature was 280°C and an injec-
tion volume of 0.5 μL was used in splitless mode. The
interface was maintained at 280°C and the detector op-
erated in scanning mode (m/z 40–800) [11]. Phenolic
compounds were identified by comparison with the data
obtained from GC/MS (retention time and fragmentation
ion) of Extrasynthese Co. authentic standards (syringic
acid, myricetin, kaempferol, luteolin, liquiritigenin, iso-
liquiritigenin, quercetin, p-coumaric acid, ferulic acid, cat-
echin, epicatechin) and with the Wiley 8 library. The
results were presented as means and followed by the
standard deviation.
Animals
Male Balb/c albino mice (20–25 g), SPF, were purchased
from CEMIB/UNICAMP (Multidisciplinary Center for
Biological Research, SP, Brazil) and used as experimental
animals. The mice were maintained in a room with con-
trolled temperature (22 ± 2°C) for a 12 h light/12 h dark
cycle, humidity (40-60%), with food (standard pellet diet)
and water provided ad libitum. The experiments were
conducted in accordance with the Guide for the Care
and Use of Laboratory Animals and counted on the
prior approval from the local Animal Ethics Committee
(CEUA, Ethics Committee on Animal Use/UNICAMP,
process number 2155–1).
Carrageenan-induced paw edema
The method by Winter et al., [12] was followed. A paw
edema was induced by subplantar injection of 0.05 mL
of lambda carrageenan (1% w/v in 0.9% of saline) into
the left hind-paw in mice. An equal volume of vehicle
was injected into the contralateral paw. The volume of
both hind-paws up to the ankle joint was measured with a
plethysmometer (model 7140, Ugo Basile) immediately be-
fore (0), 1, 2, 3, 4 and 5 hours after carrageenan. The differ-
ence in the volumes between the hind-paws was a measure
of the edema (mL). The GPE (30, 100, 300, 1000 mg/kg),
the reference drug, indomethacin (10 mg/kg), or the ve-
hicle (10 mL/kg of 0.9% of saline), were given intraperito-
neally 1/2 h or orally 1 h before the subplantar injection of
the phlogistic agent.
Dextran, histamine and serotonin induced paw edema
The anti-inflammatory activity of the extract was tested
with three phlogistic agents (dextran, histamine and
serotonin). The paw edema was induced in mice by
Table 1 Effect of i.p. administration of guava pomace extract (GPE) on a carrageenan-induced paw edema
Groups Dose (mg/kg) Mean Edema ΔV mL (percent inhibition)
1 h 2 h 3 h 4 h 5 h
Control - 0.10 ± 0.01 0.12 ± 0.01 0.14 ± 0.01 0.15 ± 0.01 0.09 ± 0.01
Indo 10 0.03 ± 0.01* 0.03 ± 0.01** 0.04 ± 0.01** 0.07 ± 0.01* 0.08 ± 0.01
(62) (68) (70) (48) (10)
GPE 300 0.05 ± 0.01* 0.05 ± 0.01* 0.08 ± 0.00* 0.09 ± 0.01 0.05 ± 0.01
(46) (56) (38) (35) (42)
GPE 100 0.05 ± 0.01* 0.08 ± 0.01* 0.10 ± 0.01 0.11 ± 0.01 0.10 ± 0.01
(51) (42) (27) (4) (13)
GPE 30 0.06 ± 0.01 0.07 ± 0.01 0.11 ± 0.01 0.09 ± 0.01 0.11 ± 0.03
(41) (40) (20) (39) (−)
ΔV = the values represent the mean difference of paw volume between the basal measure and others measures (1, 2, 3, 4 and 5 h) ± S.E.M.; n = 5-6. *p < 0.05,
**p < 0.01, significantly different when compared to control (ANOVA followed by Dunnett’s test).
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0.05 mL), histamine (50 μg/0.05 mL) or serotonin (1 μg/
0.05 mL) in 0.9% NaCl solutions, respectively. The paw
volume was recorded at 0 and 1 h after injecting histamine
or serotonin and 0, 1 and 2 h after injecting dextran. GPE
(30, 100 and 300 mg/kg), cyproheptadine (2 mg/kg) and
vehicle (10 mL/kg, NaCl 0.9%) were intraperitoneally ad-
ministered 1/2 h before eliciting the paw edema.
Neutrophils migration in the peritoneal cavity
In order to determine the neutrophil migration to the
peritoneal cavity GPE (30, 100 and 300 mg/kg) or Indo-
methacin (10 mg/kg) were administered by subcutane-
ous (s.c.) injection, 30 min before the administration of
inflammatory stimuli by intraperitoneal (i.p.) injection of
carrageenan at 500 μg/cavity. The vehicle (0.9% NaCl)
was used as negative control. Mice were killed 4 h after
the challenge (carrageenan) administration and the peri-
toneal cavity cells were harvested by washing the cavity
with 3 mL of phosphate buffered saline (PBS) containing
EDTA. The volumes recovered were similar in all experi-
mental groups and equal to approximately 95% of the
injected volume. In order to count the total number of
cells, a Newbauer chamber was used. Smears were pre-
pared using a cytocentrifuge (Cytospin 3; Shandon
Lipshaw), stained with Panotic staining kit and theTable 2 Effect of p.o administration of guava pomace extract
Groups Dose (mg/kg)
1 h 2 h
Control - 0.10 ± 0.00 0.14 ± 0
Indo 10 0.07 ± 0.01 0.09 ± 0
(30) (30)
GPE 1000 0.06 ± 0.01 0.06 ± 0.
(35) (42)
ΔV = the values represent the mean difference of paw volume between the basal m
significantly different when compared to control (ANOVA followed by Dunnett’s tesdifferent cells were counted (until 100 cells) using an op-
tical microscope (1000 ×). The results are presented as
the number of neutrophils per cavity.
Acetic acid-induced abdominal writhing
The total number of writhes following the intraperito-
neal administration of 0.2 mL of 1% (v/v) acetic acid was
recorded over a period of 30 min, starting 5 min after
the acetic acid injection. The animals were pretreated
with GPE (30, 100 and 300 mg/kg, i.p.), vehicle (0.9%
NaCl, i.p.), or indomethacin (10 mg/kg, i.p.), 20 min be-
fore administering the acetic acid [13,14].
Formalin test
The method used in the present study was similar to
that previously described by [15]. The animals were
treated with GPE (30, 100 and 300 mg/kg, i.p.), 30 min
before injection under the surface of the right hind paw
of 25 μL of 2.5% formalin (0.92% formaldehyde) in sa-
line. Indomethacin (10 mg/kg, i.p.) and morphine (5 mg/
kg, i.p.) were used as the positive control, and vehicle
(0.9% NaCl, i.p.) was used as the negative one. Animals
were observed from 0–5 min (neurogenic phase) and
15–30 min (inflammatory phase) and the time spent
licking the injected paw was recorded with a chronom-
eter and considered as indicative of nociception.(GPE) on a carrageenan-induced paw edema
Mean Edema ΔV mL (percent inhibition)
3 h 4 h 5 h
.01 0.16 ± 0.01 0.18 ± 0.01 0.16 ± 0.01
.01 0.09 ± 0.01* 0.09 ± 0.01* 0.09 ± 0.01*
(49) (67) (61)
01* 0.06 ± 0.01 0.06 ± 0.01 0.06 ± 0.01
(20) (19) (04)
easure and others measures (1, 2, 3, 4 and 5 h) ± S.E.M.; n = 5-6. *p < 0.05,
t).
Table 3 Effect of i.p. administration of guava pomace
extract (GPE) on a dextran-induced paw edema
Groups Dose (mg/kg) Mean Edema (ΔV mL)
1 h 2 h
Control 0.12 ± 0.02 0.10 ± 0.04
Cyproheptadine 2 0.04 ± 0.02*** 0.05 ± 0.03*
GPE 300 0.03 ± 0.02*** 0.03 ± 0.02**
GPE 100 0.08 ± 0.02 0.07 ± 0.02
GPE 30 0.09 ± 0.02 0.15 ± 0.04
ΔV = the values represent the mean difference of paw volume between the
basal measure and others measures (1 and 2 h) ± S.E.M.; n = 5-6. *p < 0.05,
**p < 0.01, ***p < 0.001, significantly different when compared to control
(ANOVA followed by Dunnett’s test).
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Data are expressed as the mean ± standard error of the
mean (SEM). Statistical comparisons between groups
were made using variance analyses (ANOVA) followed
by Tukey’s or Dunnett’s tests (GraphPad Prism for Win-
dows, Version 5.0). The significance was accepted when
the p value was ≤ 0.05.
Results and discussion
GPE was primarily tested for anti-inflammatory effects
using a carrageenan-induced hind-paw edema model as
a classic in vivo activity screening model. Carrageenan-
induced paw edema is found to be biphasic, the initial
phase is due to the release of histamine, serotonin and
bradykinin in the first hour after the administration of
carrageenan, and a more pronounced second phase is at-
tributed to the release of prostaglandin, bradykinin, pro-
tease, and lysosome-like substances within 2–3 h [12].
The dose-dependent swelling thickness and inhibition
effects of the extract are presented in Table 1. Indometh-
acin (10 mg/kg, i.p.) was used as positive control in this
assay, and it showed maximum inhibition (70%) after
3 hours. The extract prepared from guava pomace ad-
ministrated intraperitoneally showed inhibition (p < 0.05)
with the 300 mg/kg dose after the 1st, 2nd and 3rd
hours (46, 56 and 38%, respectively). At a dose of
100 mg/kg, the extract inhibited 51 and 42% at the 1stTable 4 Effect of i.p. administration of guava pomace extract
Groups Dose (mg/kg) Histamine (1 h
Mean Edema (ΔV mL) Pe
1 h
Control 0.12 ± 0.02
Cyproheptadine 2 0.04 ± 0.02**
GPE 300 0.07 ± 0.02*
GPE 100 0.07 ± 0.01*
GPE 30 0.13 ± 0.01
ΔV = the values represent the mean difference of paw volume between the basal m
significantly different when compared to control (ANOVA followed by Dunnett’s tesand 2nd hours, respectively (p < 0.05). There was no sig-
nificant difference in the inhibition of paw edema be-
tween the extract at a dose of 30 mg/kg and the control
group. When administrated orally, the extract at a dose
of 1000 mg/kg also inhibited paw edema (Table 2).
From the carrageenan paw edema results, since the ex-
tract showed higher activity in the first hours, guava pom-
ace extract was subjected to the paw edema induced by
dextran. This phlogistic agent once administered into the
animal paw is able to promote the consequent release of
histamine and serotonin from mast cells. Non-steroidal
anti-inflammatory agents are not able to inhibit this kind
of inflammatory process [16]. Moreover, histamine and
serotonin-induced paw edema were also used to confirm
the potential involvement of these mediators with the
anti-edematogenic effect observed. Thus, the extract
(300 mg/kg) showed significant anti-inflammatory effects
also on dextran-induced paw edema model that can be
compared with the standard drug cyproheptadine (p <
0.05). However, there was no significant difference of in-
hibition of dextran paw edema between extract (100 and
30 mg/kg) and the control group (Table 3). Furthermore,
at doses of 300 and 100 mg/kg, the extract showed signifi-
cant anti-inflammatory effects on the histamine or
serotonin-induced paw edema model (p < 0.05) (Table 4).
As to the neutrophils migration in the peritoneal cav-
ity model, the extract was able to inhibit in a significant
(p < 0.05) and dose-dependent way, at the highest dose
administered, the number of neutrophils into the peri-
toneal cavity induced by carrageenan (Figure 1). Thus,
the extract was able to reduce edemas as well as inhibit
the neutrophil migration quite significantly as evidenced
by the anti-inflammatory activity. Therefore, the anti-
inflammatory action of the guava pomace extract could
be related to the inhibition of histamine, serotonin,
bradykinin and prostaglandin, singly or in combination.
The antinociceptive activity was initially evaluated by
the acetic acid-induced abdominal writhing. The extract
was able to inhibit in a significant (p < 0.05) and dose-
dependent way the number of writhing induced by acetic
acid (Figure 2). This unspecific test is still widely used in(GPE) on a histamine- and serotonin-induced paw edema
) Serotonin (1 h)
rcent inhibition Mean Edema (ΔV mL) Percent inhibition
1 h
0.07 ± 0.02
65 0.02 ± 0.02* 65
38 0.02 ± 0.02* 68
41 0.02 ± 0.01* 62
- 0.03 ± 0.03 51
easure and other measure (1 h) ± S.E.M.; n = 5-6. *p < 0.05, **p < 0.01,
t).
C Ca Indo 30 100 300
0
2
4
6
GPE (mg/kg, i.p.)
**
*
Carrageenan (500 µg/cavity)
#
n
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Figure 1 Recruitment of neutrophils into the peritoneal cavity
induced by carrageenan. Control (C) treated with vehicle,
Indomethacin (Indo) and Guava Pomace Extract (GPE) were followed
by carrageenan injection. Mean ± S.E.M., n = 5-6. The symbol (#)
indicates statistical difference compared to the vehicle group. The
symbol (*) indicates statistical difference compared to the
carrageenan group (ANOVA followed by Tukey’s test, *p < 0.05
and **p < 0.01).
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trally and peripherally, besides being considered a test
for visceral inflammatory pain [13,14]. In order to
proceed with the evaluation of the antinociceptive effect
of the guava pomace extract, the formalin test was car-
ried out. The administration of the extract at doses of 30
and 300 mg/kg (Figure 3) reduced the reaction time in-
duced by formalin (p < 0.01 and p < 0.001), respectivelyC Indo 30 100 300
0
20
40
60
80
*
*
*
*
__________________
GPE (mg/kg, i.p.)
N
um
be
r o
f w
rit
he
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Figure 2 Effect of i.p. injection of guava pomace extract on
abdominal constriction induced by acetic acid in mice. Control
(C) treated with vehicle, Indomethacin (Indo) 10 mg/kg, Guava
Pomace Extract (GPE). Mean ± S.E.M., n = 5-6. *p < 0.05 compared to
the control group (ANOVA followed by Dunnett’s test).in phase I (neurogenic phase), where the response is re-
lated with a direct activation of nociceptors. In phase II
(inflammatory phase), marked by a local release of en-
dogenous mediators, which generate a local inflammatory
response [15], the extract was also active at the dose of
300 mg/kg (p < 0.01). Filho et al. demonstrated that quer-
cetin was able to inhibit both phases of formalin-induced
pain, with ID50 values of 374.10 mmol/kg and
103.00 mmol/kg for neurogenic and inflammatory phases,
respectively [17]. Thus, extracts containing quercetin, such
as GPE, could, therefore, also inhibit both phases in the
formalin test.
From the chemical analysis, the present study found
total phenolic values of 3.40 ± 0.09 mg GAE/g in the
guava pomace extract. Literature data have shown in
aqueous organic extracts of the pulp and peel portions
of guava, estimated by the Folin-Ciocalteu’s method,
values of 58.7 ± 4.0 and 26.3 ± 0.8 mg GAE/g, respect-
ively [1]. Such difference between the values of total
phenols detected in the fruit by Jiménez-Escrig et al. [1]
and the pomace extract evaluated in the present study
was already predictable, since the pressing process to
which it was submitted in order to obtain the juice was
able to remove most part of these compounds. Despite
the low level of phenolic compounds present in the
pomace, interesting results of the biological activity were
demonstrated.
To determine the possible active compounds involved
with the anti-inflammatory and antinociceptive effects of
the pomace guava extract revealed in the present study,
a GC/MS analysis was used, through which thirteen
compounds were identified, among them epicatechin,
quercetin, myricetin, isovanilic and gallic acids (Table 5).
In general, the biological properties of guava have been
already associated with its phenolic compounds, such as
protocatechunic, ferulic, ascorbic, gallic and caffeic acids
and quercetin [5,18]. In the present study, one of the
identified compounds that could be responsible for the
biological activity exhibited is the flavonoid quercetin,
commonly known to have both antioxidant and anti-
inflammatory effects, which inhibits NO and PGE2 activ-
ities. Furthermore the antinociceptive action of quercetin
was also demonstrated through mechanisms that involve
interaction with L-arginine-nitric oxide, serotonin, and
GABAergic systems [19], moreover by inhibiting the
pro-nociceptive cytokine production (e.g., TNF alpha
and IL-1 beta) and the oxidative imbalance mediation of
inflammatory pain [20].
A possible relationship between catechins and their in-
volvement with the anti-inflammatory activity of the
guava pomace extract can be compared with the immu-
nomodulatory activity of black tea evaluated by
Chattopadhyay et al., [20]. The major bioactive constitu-
ents of Camellia sinensis are catechins, which may have
C Indo Morph 30 100 300
0
20
40
60
80
GPE (mg/kg, i.p.)
***
*** **
Phase I
Ti
m
e 
(s)
C Indo Morph 30 100 300
0
50
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150
200
GPE (mg/kg, i.p.)
**
**
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m
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Figure 3 Effect of i.p. injection of guava pomace extract on formalin-induced nociception in mice. Control (C), Indo (Indomethacin
10 mg/kg), Morph (Morphine 10 mg/kg), Guava Pomace Extract (GPE). Mean ± S.E.M., n = 5-6. *p < 0.05, **p < 0.01 and ***p < 0.001 compared
to the control group (ANOVA followed by Dunnett’s test).
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the tea decoction evaluated using paw edema induced
by carrageenan and dextran [20]. Many biological ef-
fects have been reported for (+) catechins, including
anticarcinogen, cardiopreventive, antimicrobial, anti-
viral, neuro-protective [20] and anti-inflammatory [21]
effects. Similarly, the epicathechin identified in the guava
pomace extract could be related with the anti-
inflammatory effects showed in paw edema models in-
duced by different phlogistic agents (Tables 1, 2, 3, 4) and
neutrophils migration in the peritoneal cavity (Figure 1).
Finally, in relation to the anti-inflammatory and anal-
gesic properties of guava, most studies refer to the leaf
extracts and were evaluated on several experimen-
tal models [5,7,8]. In this paper, a promising anti-Table 5 Phenolic compounds present in the guava pomace ex
Peak number Compound RT (min)
1 Phosphoric acid, tristrimethylsilyl 5.789
2 Beta-caryophyllene 6.978
3 Malic acid (TMS) 7.219
4 Alpha-selinene 7.460
5 Trimethylsilyl 3-phenyl-2-propenoate 7.630
11 Isovanilic acid 8.87
16 Tris (trimethylsilyl) 2-[(trimethylsilyl)oxy]-1,2,
3-propanetricarboxylate
9.176
18 Beta-l-mannofuranose, 6-deoxy-1,2,3,
5-tetrakis-o-(trimethylsilyl)
9.314
19 Glucofuranoside, methyl 2,3,5,
6-tetrakis-o-(trimethylsilyl)-, alpha-d-
9.353
25 Gallic acid 9.89
27 Hexadecanoic acid, trimethylsilyl ester 10.311
31 Oleic acid, trimethylsilyl ester 11.425
38 Epicatechin 17.41
40 Myricetin 20.511
41 Quercetin 20.601
Peaks 6–11; 12–15; 17; 20–24; 28–30; 32–37 and 39 are not identified.inflammatory and antinociceptive potential of the guava
pomace extract was shown for the first time, despite the
fact that its mechanism of action should be further
investigated.
Conclusions
Thus, we conclude that the presence of bioactive sub-
stances such as quercetin and epicatechin, as well as the
important effects demonstrated in animal models, sug-
gest that guava pomace could be a new source of com-
pounds with anti-inflammatory and antinociceptive
activities. Besides, applying this material in bioprocesses
provides a wide range of alternative substrates, therefore,
helping to solve pollution problems related to its
disposal.tract identified by GC-MS
% Area Ions (m/z)
2.39 299 (100), 73 (47), 300 (24), 314 (17), 301 (13); 341 (M+)
0.65 41 (100), 93 (93), 133 (87), 91 (85), 69 (83); 189 (M+)
0.73 73 (100), 147 (54), 233 (24), 245 (14), 133 (12); 335 (M+)
0.59 93 (100), 107 (86), 189 (85), 91 (81), 41 (78), 205 (M+)
1.58 205 (100), 131 (87), 103 (67), 161 (62), 77 (48); 221 (M+)
0.67 73 (100), 297 (67), 267 (48), 217 (42), 312 (40), 357 (M+)
3.69 73 (100), 273 (74), 147 (51), 217 (19), 347 (19); 467 (M+)
1.78 73 (100), 217 (96), 204 (42), 191 (23), 147 (22); 347 (M+)
2.79 217 (100), 73 (99), 218 (49), 129 (48), 191 (23); 363 (M+)
3.72 73 (100), 281 (62), 458 (38), 332 (30), 147 (26); 464 (M+)
2.86 117 (100), 73 (79), 313 (74), 75 (58), 132 (52), 329 (M+)
1.51 73 (100), 117 (97), 75 (76), 129 (64), 339 (59), 354 (M+)
0.61 368 (100), 73 (56), 355 (46), 369 (34), 650 (23), 654 (M+)
1.68 735 (100), 736 (66), 737 (39), 73 (36), 575 (33), 740 (M+)
4.94 647 (100), 648 (55), 649 (35), 73 (26), 650 (12), 663 (M+)
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